Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -125%. A quarter ago, it was expected that this company would post earnings of $0.06 per share when it actually produced earnings of $0.07, delivering a surprise of 16.67%.Over the last four quarters, the company h ...

Cytek Biosciences (CTKB) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Thank you for standing by. At this time, I would like to welcome everyone to the Cytec Biosciences First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I would now like to turn the conference over to Paul Goodson, Head of Investor Relations. Please go ahead, sir. Speaker1 Thank you, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 00 ...

Operating expenses were $35.1 million for the first quarter of 2025, a 4.1% increase from $33.7 million in the first quarter of 2024. Research and development expenses were $9.7 million for the first quarter of 2025 compared to $9.8 million for the first quarter of 2024. Total revenue for the first quarter of 2025 was $41.5 million, a 7.6% decrease compared to the first quarter of 2024. The decrease in revenue reflected a slowdown in product sales in the US and EMEA, partially offset by strength in APAC and ...

FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First Quarter Highlights Total revenue for the first quarter of 2025 was $41.5 million, representing a 7.6% decrease compared to the first quarter of 2024Expanded to a total installed base of 3,149 Cytek instruments, including the Amnis® and Guava® instruments shipped ...

I rate Cytek Biosciences (NASDAQ: CTKB ) with a Buy rating. I think the net losses that the company has reported since mid-2022 do not correspond with the 79.82% plunge in its stock price. Cytek hasDaniel Mellado is an economist from Carabobo University with a Master's Degree in Statistics from Simon Bolivar University, both obtained in Venezuela.Daniel worked analyzing the agricultural commodity market and the financial investment portfolio for an agribusiness group. Then, he managed two teams, one in trad ...

Core Insights - Cytek Biosciences is committed to advancing cell analysis through its patented Full Spectrum Profiling™ (FSP) technology, which will be showcased at key industry events such as CYTO 2025 and IMMUNOLOGY2025 [1][2][5] Company Overview - Cytek Biosciences, Inc. (Nasdaq: CTKB) is a leading company in cell analysis solutions, focusing on high-resolution, high-content, and high-sensitivity tools [6][7] - The company’s FSP technology enhances multiplexing capabilities with precision and sensitivity, positioning it as a pioneer in spectral flow cytometry [6][2] Industry Events - At IMMUNOLOGY2025, Cytek will present its complete cell analysis solutions, including instruments, reagents, and software, aimed at advancing research and discovery [3][4] - The company will also host a workshop on in-depth characterization of mouse immune responses during the event [4] - CYTO 2025 will feature Cytek as a Platinum sponsor, where it will showcase technology designed to accelerate scientific discovery [4][5] Strategic Goals - Cytek aims to make flow cytometry technology more accessible and scalable, unlocking new opportunities in high-growth areas such as immunology, oncology, and cell therapy [2][5] - The company emphasizes its commitment to delivering innovative and flexible solutions to empower researchers and accelerate breakthroughs in scientific advancement [5]

He leads the investing group Beyond the Wall Investing with features that include: a fundamentals-based portfolio, weekly analysis on insights from institutional investors, regular alerts for short-term trade ideas based on technical signals, ticker feedback by request from readers, and community chat. Learn more With just one subscription to Beyond the Wall Investing , you can save thousands of dollars a year on equity research reports from banks. You'll keep your finger on the pulse and have access to the ...

FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investors” section of th ...

Core Viewpoint - Cytek Biosciences has launched the Cytek® Muse® Micro cell analyzer, a next-generation instrument that enhances flow cytometry capabilities while being affordable and user-friendly, targeting various markets including cell and gene therapy and drug discovery [1][2][3] Product Features - The Muse Micro cell analyzer builds on the original Muse system, which was the most compact flow cytometer when introduced in 2013, and has a significant installed base globally [2] - It features a 488 nm blue laser, five parameters including forward and side scatter, and three fluorescent channels, making routine assays faster and more accessible [2][5] - The compact design measures 8 in x 10 in (20 cm x 25 cm) and utilizes advanced microcapillary technology for precise cell counts without the need for calibration beads [5] Market Opportunities - The Muse Micro system aims to make advanced cellular instrumentation accessible to smaller labs and resource-limited facilities, thus expanding Cytek's market reach [3] - It is designed for diverse testing environments across industries such as drug discovery, biopharma, and water quality testing, making it suitable for both academic and industrial laboratories [3][4] Company Overview - Cytek Biosciences is a leading cell analysis solutions company known for its Full Spectrum Profiling™ (FSP®) technology, which enhances multiplexing with precision and sensitivity [4] - The company offers a comprehensive suite of solutions including core FSP instruments, reagent preparation systems, and imaging products under various brands [4]